NCT07049237Completed
Evidence-Based Nursing for Fatigue and Quality of Life in Lung Cancer Chemotherapy
Effects of Evidence-Based Nursing Under a Quantitative Assessment Strategy on Cancer-Related Fatigue, Self-Management Ability, and Quality of Life in Lung Cancer Patients Undergoing Chemotherapy
Source: ClinicalTrials.gov · Last updated 3 Jul 2025
Brief summary (registry, in English)
This prospective randomized controlled trial investigated the effects of an evidence-based nursing intervention under a quantitative assessment strategy (EB-NQAS), utilizing the Edmonton Symptom Assessment Scale (ESAS), on cancer-related fatigue, self-management ability, and quality of life in lung cancer patients undergoing chemotherapy. Outcomes were compared to a group receiving routine nursing care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 150 (actual)
- First submitted
- 25 Jun 2025
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- The First Hospital of Hebei Medical University
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07049237
What you commit to
- Study type: Interventional
- Participants enrolled: 150
- From 1 Jan 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent radiotherapy or immunotherapy.
Other illness
- Active neurological disorders (e.g., stroke, epilepsy) affecting symptom reporting.
- Acute infectious diseases (e.g., tuberculosis with sputum positivity).
- Known allergies to chemotherapy drugs (e.g., platinum agents).
- Acute illnesses requiring hospitalization (e.g., pneumonia, myocardial infarction).
- Secondary malignancies (pathologically confirmed).
- Chemotherapy contraindications (e.g., uncontrolled heart failure).
Lab values
- Concurrent severe organ dysfunction (Child-Pugh score ≥B for liver; estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m² for kidney).
Other
- Inability to communicate in the local language (assessed via nurse interview).
- Participation in other interventional clinical trials within 3 months.
Who the study is looking for
- Pathologically or radiologically confirmed lung cancer (World Health Organization \[WHO\] 2021 diagnostic criteria).
- Scheduled to receive first-line chemotherapy (platinum-based regimen).
- Karnofsky Performance Status (KPS) score ≥60.
- Estimated survival time \>6 months (assessed by treating oncologist).
- Normal mental and cognitive function (Mini-Mental State Examination \[MMSE\] score ≥24).
- Voluntary participation and signed informed consent.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.